We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

111 hedge funds and large institutions have $408M invested in Enanta Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

71% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 28

13% more funds holding

Funds holding: 98 → 111 (+13)

3% less capital invested

Capital invested by funds: $419M → $408M (-$11.2M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

61% less call options, than puts

Call options by funds: $638K | Put options by funds: $1.62M

Holders
111
Holders Change
+13
Holders Change %
+13.27%
% of All Funds
3.22%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
24
Increased
48
Reduced
28
Closed
11
Calls
$638K
Puts
$1.62M
Net Calls
-$981K
Net Calls Change
-$1.16M

Top Buyers

1
Marshall Wace
Marshall Wace
United Kingdom
+$12.5M
2
SAM
Senzar Asset Management
New York
+$12.4M
3
GC
Guggenheim Capital
Illinois
+$7.68M
4
EAM
Eagle Asset Management
Florida
+$4.92M
5
NI
Numeric Investors
Massachusetts
+$4.43M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$51.4M
2
WSA
Wall Street Associates
California
-$2.4M
3
AAM
Aureus Asset Management
Massachusetts
-$2.39M
4
CCM
Cadence Capital Management
Massachusetts
-$2.38M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$79.5M +$211K +5,300 +0.3%
CCM
2
Consonance Capital Management
New York
$63.3M +$2.11M +53,012 +3%
EAM
3
Eagle Asset Management
Florida
$36.6M +$4.92M +123,514 +15%
SAM
4
Senzar Asset Management
New York
$22.4M +$12.4M +311,775 +122%
GT
5
Glenmede Trust
Pennsylvania
$13M +$4.09M +102,486 +46%
Marshall Wace
6
Marshall Wace
United Kingdom
$12.5M +$12.5M +313,211 +9,742%
RCM
7
RA Capital Management
Massachusetts
$9.89M -$51.4M -1,289,586 -84%
BFA
8
BlackRock Fund Advisors
California
$9.86M -$218K -5,457 -2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$9.59M +$2.49M +62,350 +35%
GC
10
Guggenheim Capital
Illinois
$8.13M +$7.68M +192,691 +1,518%
WSA
11
Wall Street Associates
California
$6.3M -$2.4M -60,100 -27%
BIT
12
BlackRock Institutional Trust
California
$6.04M +$1.45M +36,386 +31%
ICRM
13
Insight Capital Research & Management
California
$5.41M -$864K -21,678 -14%
State Street
14
State Street
Massachusetts
$4.93M +$75.7K +1,900 +2%
Northern Trust
15
Northern Trust
Illinois
$4.8M +$2.59M +64,879 +115%
NI
16
Numeric Investors
Massachusetts
$4.4M +$4.43M +111,200 New
BLM
17
Bennett Lawrence Management
New York
$4.37M -$316K -7,930 -7%
MAA
18
Managed Account Advisors
New Jersey
$4.17M +$526K +13,195 +14%
SCM
19
Sarissa Capital Management
Connecticut
$4.16M – – –
TC
20
TFS Capital
Pennsylvania
$3.71M +$3.74M +93,771 New
B
21
Bailard
California
$3.62M – – –
QBFM
22
QS Batterymarch Financial Management
New York
$3.36M +$102K +2,558 +3%
Renaissance Technologies
23
Renaissance Technologies
New York
$3.29M +$1.14M +28,677 +53%
Deutsche Bank
24
Deutsche Bank
Germany
$3.05M +$1.94M +48,711 +171%
Invesco
25
Invesco
Georgia
$3M +$15.3K +384 +0.5%
1
2 3 4 5

ENTA Hedge Fund Activity: Q3 2014 in Review

111 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2014, worth a combined $408M — down 2.7% from $419M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ENTA positions and 11 closed out — a net gain of 13 holders — while 48 added to existing stakes and 28 trimmed.

The largest buyer was Marshall Wace, adding an estimated $12.5M. The largest seller was RA Capital Management, cutting an estimated $51.4M.

  • 111 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2014, up from 98 in Q2 2014.
  • Funds reported $408M of Enanta Pharmaceuticals stock for Q3 2014, down 2.7% quarter-over-quarter.
  • 24 funds opened new Enanta Pharmaceuticals positions in Q3 2014 and 11 closed out, a net change of +13 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2014 was Marshall Wace, an estimated $12.5M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2014 was RA Capital Management, an estimated $51.4M sold.

Based on aggregated 13F filings for Q3 2014.